Nuclear imaging in cardiovascular medicine

Essential Cardiology: Principles and Practice: Second Edition

Volumn , Issue , 2006, Pages 221-243

  Jain, Diwakar ^a   Zaret, Barry L ^b,c  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b Section of Cardiovascular Medicine   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84891425431     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-59259-918-9_13     Document Type: Chapter

References (82)

1. Jain D, Strauss HW. Introduction to nuclear cardiology. In: Dilsizian V, Narula J, eds. Atlas of Nuclear Cardiology. London, Current Science 2003, pp. 1-18.
2. Kaul S, Boucher CA, Newell JB, et al. Determination of the quantitative thallium imaging variables that optimize detection of coronary artery disease. J Am Coll Cardiol 1986;7:527-537.
3. Wackers FJTh, Fetterman RC, Mattera JA, Clements JP. Quantitative planar thallium-201 stress scintigraphy: a critical evaluation of the method. Sem Nucl Med 1985;15:46-66.
4. Jain D, Zaret BL. Nuclear imaging techniques for the assessment of myocardial viability. Cardiol Clin 1995;13; 43-57.
5. Wackers FJTh. The maze of myocardial perfusion imaging protocols in 1994. J Nucl Cardiol 1994;1:180-188.
6. Dilsizian V, Rocco T, Freedman N, et al. Enhanced detection of ischemic but viable myocardium by the reinjection of thallium after stress-redistribution imaging. N Engl J Med 1990;323:141-146.
7. Kayden DS, Sigal S, Soufer R, et al. Thallium-201 for assessment of myocardial viability: quantitative comparison of 24-hour redistribution imaging with imaging after reinjection at rest. J Am Coll Cardiol 1991;18:1480-1486.
8. 99mTechnetium labeled myocardial perfusion imaging agents. Semi Nucl Med 1999;29;221-236.
9. Zaret BL, Rigo P, Wackers FJTh, et al., and the Tetrofosmin International Trial Group. Myocardial perfusion imaging with technetium-99m tetrofosmin: comparison to thallium-201 imaging and coronary angiography in a phase III multicenter trial. Circulation 1995;91:313-319.
10. 99mTc-tetrofosmin: myocardial perfusion imaging agent: implications for a one day imaging protocol. J Nucl Med 1993;34:1254-1259.
11. Joseph B, Bhargava KK, Kandimala J, et al. The nuclear imaging agent sestamibi is a substrate for both MDR1 and MDR2 p-glycoprotein genes. Eur J Nucl Med 2003;30:1024-1031.
12. Vanzetto G, Fagret D, Pasqualini R, et al. Biodistribution, dosimetry, and safety of myocardial perfusion imaging agent 99mTcN-NOET in healthy volunteers. J Nucl Med 2000;41:141-148.
13. Iskandrian AS, Heo J, Kong B, et al. Use of technetium-99m isonitrile in assessing left ventricular perfusion and function at rest and during exercise in coronary artery disease and comparison with coronary angiography and exercise thallium-201 SPECT imaging. Am J Cardiol 1989;64:270-275.
14. Eagle KA, Singer DE, Brewster DC, et al. Dipyridamole-thallium scanning in patients undergoing vascular surgery: optimizing preoperative evaluation of cardiac risk. JAMA 1987;257:2185-2189.
15. Samady H, Wackers FJ, Zaret BL, et al. Pharmacological stress perfusion imaging with adenosine: role of simultaneous low level treadmill exercise. J Nucl Cardiol 2002;9:188-196.
16. Taillefer R, Amyot R, Turpin S, et al. Comparison between dipyridamole and adenosine as pharmacologic coronary vasodilators in detection of coronary artery disease with thallium 201 imaging. J Nucl Cardiol 1996;3:204-211.
17. Lette J, Tatum JL, Fraser S, et al. Safety of dipyridamole testing in 73, 806 patients: the Multicenter Dipyridamole Safety Study. J Nucl Cardiol 1995;2:3-17.
18. Holly TA, Satran A, Bromet DS, et al. The impact of adjunctive adenosine infusion during exercise myocardial perfusion imaging: results of the Both Exercise and Adenosine Stress Test (BEAST) trial. J Nucl Cardiol 2003;10: 291-296.
19. Glover DK, Ruiz M, Takehana K, et al. Pharmacological stress myocardial perfusion imaging with the potent and selective A(2A) adenosine receptor agonists ATL193 and ATL146e administered by either intravenous infusion or bolus injection. Circulation 2001;104:1181-1187.
20. Udelson JE, Heller GV, Wackers FJ, et al. Randomized, controlled dose-ranging study of the selective adenosine A2A receptor agonist binodenoson for pharmacological stress as an adjunct to myocardial perfusion imaging. Circulation 2004;109:457-464.
21. 99mTc sestamibi uptake, and systolic wall thickening in the presence of coronary artery stenoses: implications for dobutamine stress testing. Circulation 1997;96:2353-2360.
22. Shehata AR, Ahlberg AW, Gillam LD, et al. Direct comparison of arbutamine and dobutamine stress testing with myocardial perfusion imaging and echocardiography in patients with coronary artery disease. Am J Cardiol 1997;80: 716-720.
23. Wackers FJ. Science, art, and artifacts: how important is quantification for the practicing physician interpreting myocardial perfusion studies? J Nucl Cardiol 1994;1:S109-S117.
24. Ficaro EP, Corbett JR. Advances in quantitative perfusion SPECT imaging. J Nucl Cardiol 2004;11:62-70.
25. Heller GV, Links J, Bateman TM, et al. American Society of Nuclear Cardiology and Society of Nuclear Medicine joint position statement: attenuation correction of myocardial perfusion SPECT scintigraphy. J Nucl Cardiol 2004; 11:229-230.
26. Panjrath G, Jain D. Myocardial perfusion imaging in a patient with chest pain. J Nucl Cardiol 2004;11:515-517.
27. Wackers FJ, Zaret BL. Radionuclide stress myocardial perfusion imaging: the future gatekeeper for coronary angio-graphy [editorial]. J Nucl Cardiol 1995;2:358-359.
28. Bateman TM, O'Keefe JH, Dong VM, et al. Coronary angiographic rates after stress single photon emission computed tomographic scintigraphy. J Nucl Cardiol 1995;2:217-223.
29. Jain D, Lahiri A, Raftery EB. Lung thallium uptake on rest, stress and redistribution cardiac imaging: state-of-the-art-review. Am J Card Imag 1990;4:303-309.
30. Gill JB, Ruddy TD, Newell JB, et al. Prognostic importance of thallium uptake by the lungs during exercise in coronary artery disease. N Engl J Med 1987;317:1485-1489.
31. Taylor AJ, Sackett MC, Beller GA. The degree of ST-segment depression on symptom-limited exercise testing: relation to the myocardial ischemic burden as determined by thallium-201 scintigraphy. Am J Cardiol 1995;75: 228-231.
32. Iskander S, Iskandrian AE. Risk assessment using single-photon emission computed tomographic technetium-99m sestamibi imaging. J Am Coll Cardiol 1998;32:57-62.
33. Thomas GS, Miyamoto MI, Morello P, et al. Technetium-99m sestamibi myocardial perfusion imaging predicts clinical outcome in the community outpatient setting: The Nuclear Utility in the Community (NUC) Study. J Am Coll Cardiol 2004;43:213-223.
34. Raiker K, Sinusas AJ, Wackers FJ, Zaret BL. One-year prognosis of patients with normal planar or single-photon emission computed tomographic technetium 99m labeled sestamibi exercise imaging. J Nucl Cardiol 1994;1:449-456.
35. Gibson RS, Watson DD, Craddock GB, et al. Prediction of cardiac events after uncomplicated myocardial infarction: a prospective study comparing predischarge exercise thallium-201 scintigraphy and coronary angiography. Circulation 1983;68:321-336.
36. Jain D, Wackers FJTh, Zaret BL. Radionuclide imaging techniques in the thrombolytic era. In: Becker R, ed. Modern Era of Coronary Thrombolysis, 1st ed. Kluwer Academic Publishers, Norwell, MA, 1994, pp. 195-218.
37. Udelson JE, Beshansky JR, Ballin DS, et al. Myocardial perfusion imaging for evaluation and triage of patients with suspected acute cardiac ischemia: a randomized controlled trial. JAMA 2002;288:2693-2700.
38. Abbott BG, Abdel-Aziz I, Nagula S, et al. Selective use of single-photon emission computed tomography myocardial perfusion imaging in a chest pain center. Am J Cardiol 2001;87:1351-1355.
39. Abbott BG, Jain D. Nuclear cardiology in the evaluation of acute chest pain in the emergency department. Echocar-diography 2000;17:597-604.
40. Abbott BG, Jain D. Impact of myocardial perfusion imaging on clinical management and the utilization of hospital resources in suspected acute coronary syndromes. Nucl Med Comm 2003;24:1061-1069.
41. Jain D, Fleisher LA, Zaret BL. Diagnosing perioperative myocardial infarction in noncardiac surgery. Int Anesthesi-ology Clin 1992;30:199-216.
42. Leppo JA. Preoperative cardiac risk assessment for noncardiac surgery. Am J Cardiol 1995;75:42D-51D.
43. Fleisher LA, Rosenbaum SH, Nelson AH, et al. Preoperative dipyridamole thallium imaging and Holter monitoring as a predictor of perioperative cardiac events and long term outcome. Anesthesiology 1995;83:906-917.
44. 201Tl imaging in detection of myocardial viability and prediction of improvement in left ventricular function after coronary bypass surgery in patients with severely depressed left ventricular function. Circulation 1993;87:1630-1641.
45. Caner B, Beller GA. Are technetium-99m-labeled myocardial perfusion agents adequate for detection of myocar-dial viability? Clin Cardiol 1998;4:235-242.
46. He ZX, Verani MS, Liu XJ, Nitrate-augmented myocardial imaging for assessment of myocardial viability [editorial]. J Nucl Cardiol 1995;2:352-357.
47. Borges-Neto S, Shaw LJ, Kesler KL, et al. Prediction of severe coronary artery disease by combined rest and exercise radionuclide angiocardiography and tomographic perfusion imaging with technetium 99m-labeled sestamibi: a comparison with clinical and electrocardiographic data. J Nucl Cardiol 1997;4:189-194.
48. Lee KL, Proyer DB, Pieper KS, et al. Prognostic value of radionuclide angiography in medically treated patients with coronary artery disease: a comparison with clinical and catheterization variables. Circulation 1990;82:1705-1717.
49. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-691.
50. Schwartz RG, McKenzie B, Alexander J, et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy: seven-year experience using serial radionuclide angiocardiography. Am J Med 1987; 82:1109-1118.
51. Jain D, Zaret BL. Antimyosin cardiac imaging: will it play a role in the detection of doxorubicin cardiotoxicity? (editorial) J Nucl Med 1990;31:1970-1975.
52. Jain D. Cardiotoxicity of doxorubicin and other anthracyclines derivatives. J Nucl Cardiol 2000;7:53-62.
53. Mitani I, Jain D, Joska TM, et al. Doxorubicin cardiotoxicity: prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era. J Nucl Cardiol 2003;10:132-139.
54. Bonow RP, Kent KM, Rosing DR, et al. Exercise-induced ischemia in mildly symptomatic patients with coronary artery disease and preserved left ventricular function: identification of subgroups at risk of death during medical therapy. N Engl J Med 1984;311:1339-1345.
55. Zaret BL, Jain D. Monitoring of left ventricular function with miniaturized non-imaging detectors. In: Zaret BL, Beller GA, eds. Nuclear Cardiology: State of the Art and Future Directions, 2nd ed. Mosby Year Book, St. Louis, 1999, pp. 191-200.
56. Burg MM, Jain D, Soufer R, et al. Role of behavioral and psychological factors in mental stress induced silent left ventricular dysfunction in coronary artery disease. J Am Coll Cardiol 1993;22:440-448.
57. Jain D, Burg MM, Soufer RS, Zaret BL. Prognostic significance of mental stress induced left ventricular dysfunction in patients with coronary artery disease. Am J Cardiol 1995;76:31-35.
58. Jiang W, Babyak M, Krantz DS, et al. Mental stress-induced myocardial ischemia and cardiac events. JAMA 1996; 275:1651-1656.
59. Krantz DS, Santiago HT, Kop WJ, et al. Prognostic value of mental stress testing in coronary artery disease. Am J Cardiol 1999;84:1292-1297.
60. Jain D, Lahiri A, Raftery EB. Immunoscintigraphy for detecting acute myocardial infarction without electrocardio-graphic changes. Br Med J 1990;300:151-153.
61. Dec GW, Palacios I, Yasuda T, et al. Antimyosin antibody cardiac imaging: its role in the diagnosis of myocarditis. J Am Coll Cardiol 1990;16:97-104.
62. Ballester M, Bordes R, Tazelaar HD, et al. Evaluation of biopsy classification for rejection: relation to detection of myocardial damage by monoclonal antimyosin antibody imaging. J Am Coll Cardiol 1998;31:1357-1361.
63. Carrio I, Estorch M, Berna L, et al. Indium-111-antimyosin and iodine-123-MIBG studies in early assessment of doxo-rubicin cardiotoxicity. J Nucl Med 1995;36(11):2044-2049.
64. Narula J, Petrov A, Pak C, et al. Hyperacute visualization of myocardial ischemic injury: comparison of Tc-99m glucarate, thallium-201 and indium-111-antimyosin. J Am Coll Cardiol 1994;23:317.
65. Mariani G, Villa G, Rossettin PF, et al. Detection of acute myocardial infarction by 99mTc-labeled D-glucaric acid imaging in patients with chest pain. J Nucl Med 1999;40:1832-1839.
66. Hofstra L, Liem IH, Dumont EA, et al. Visualisation of cell death in vivo in patients with acute myocardial infarction. Lancet 2000;356:209-212.
67. Blankenberg F, Mari C, Strauss HW. Imaging cell death in vivo. Q J Nucl Med 2003;47:337-348.
68. Schelbert HR. Positron emission tomography as a biochemical probe for human myocardial ischemia. In: Zaret BL, Kaufman L, Dunn R, Berson A, eds. Frontiers of Cardiac Imaging. Raven Press, New York, 1993, pp. 53-70.
69. Bax JJ, Patton JA, Poldermans D, et al. 18-Fluorodeoxyglucose imaging with positron emission tomography and single photon emission computed tomography: cardiac applications. Semin Nucl Med 2000;30:281-298.
70. Jain D, McNulty PH. Exercise-induced myocardial ischemia: can this be imaged with F-18-fluorodeoxyglucose? (editorial) J Nucl Cardiol 2000;7:286-288.
71. He ZX, Shi RF, Wu YJ, et al. Direct imaging of exercise induced myocardial ischemia in coronary artery disease. Circulation 2003;108:1208-1213.
72. Gould KL, Taegtmeyer H. Myocardial ischemia, fluorodeoxyglucose, and severity of coronary artery stenosis: the complexities of metabolic remodeling in hibernating myocardium (letter to the editor and response). Circulation 2004;109:e167-e170.
73. Berry CR, Garg PK, DeGrado TR, et al. Para-[18F]fluorobenzylguanidine kinetics in a canine coronary artery occlusion model. J Nucl Cardiol 1996;3:119-129.
74. Morita K, Tsukamoto E, Tamaki N. Perfusion-BMIPP mismatch: specific finding or artifact? Int J Cardiovasc Imaging 2002;18:279-282.
75. Narula J, Petrov A, Bianchi C, et al. Noninvasive localization of experimental atherosclerotic lesions with mouse/human chimeric Z2D3 F(ab')2 specific for the proliferating smooth muscle cells of human atheroma. Imaging with conventional and charge-modified antibody fragments. Circulation 1995;92:474-484.
76. Jain D, Kulkarni P, Kolodgie FD, et al. Noninvasive imaging of atherosclerotic plaques with In-111 labeled lipid-seeking coproporphyrin. J Am Coll Cardiol 2000;35(Suppl A):493-A.
77. Kietselaer BL, Reutelingsperger CP, Heidendal GA, et al. Noninvasive detection of plaque instability with use of radiolabeled annexin-5 in patients with carotid-artery atherosclerosis. N Engl J Med 2004;350:1472-1473.
78. Dilsizian V, Narula J, eds. Atlas of Nuclear Cardiology, 1st ed. Current Medicine, 2003.
79. Gerson MC. Cardiac Nuclear Medicine, 3rd ed. McGraw-Hill, New York, 1997.
80. Heller GV, Hendel RC. Nuclear Cardiology: Practical Applications, 1st ed. McGraw-Hill, New York, 2004.
81. Iskandrian AS, Verani MS. New Developments in Cardiac Nuclear Imaging, 1st ed. Futura Publishing, 1998
82. Zaret BL, Beller GA, eds. Nuclear Cardiology: State of the Art and Future Directions, 3rd ed. Mosby Year Book, St. Louis, 2005.